Abstract
Colon adenocarcinoma (COAD) remains a leading cause of cancer-related mortality worldwide, partly due to the lack of robust biomarkers for early diagnosis and accurate prognosis. Glycoproteins play critical roles in tumorigenesis and may serve as promising sources of biomarkers. This study aimed to identify glycoprotein-related candidate diagnostic and prognostic biomarkers for COAD through integrated bioinformatics approaches and experimental validation. Gene expression profiles and clinical information of COAD patients were obtained from The Cancer Genome Atlas database (TCGA). The expression data for genes associated with glycoprotein were retrieved from the UniProt database. Furthermore, we assessed the mRNA expression levels of the glycoprotein FJX1 in COAD and rectal adenocarcinoma tissues through in situ hybridization (ISH) staining using tissue microarrays. A total of 228 glycoprotein-related differentially expressed genes (DEGs) were identified, enriched in the extracellular matrix organization and signaling pathways such as PI3K-Akt and cAMP. Protein-protein interaction (PPI) network analysis revealed 10 hub genes (LIFR, CNTFR, LIF, CSF2, IL1A, CSF3, F2, FGA, FGFR2, INHBA). Survival screening and multivariate Cox regression identified FJX1 as an independent prognostic factor for overall survival after adjusting for age and stage. FJX1 mRNA was significantly overexpressed in COAD tissues compared to normal (p < 0.001), and high FJX1 expression correlated with advanced T stage, M stage, and pathological stage. ISH confirmed elevated FJX1 mRNA in tumors. Immune infiltration analysis further revealed that high FJX1 expression was associated with increased infiltration of M0 macrophages and neutrophils, and decreased resting memory CD4+ T cells, suggesting a potential role in shaping the immunosuppressive tumor microenvironment. GSEA revealed significant enrichment of MAPK signaling in high-FJX1 tumors. In conclusion, this study identified 10 glycoprotein-related hub genes as candidate diagnostic biomarkers warranting further validation and established FJX1 as an independent prognostic biomarker for COAD. FJX1 overexpression is associated with tumor progression and may be linked to MAPK signaling as well as immune modulation. These findings provide a foundation for glycoprotein-based biomarker development in COAD.
Similar content being viewed by others
Abbreviations
- COAD:
-
Colon adenocarcinoma
- TCGA:
-
The cancer genome atlas database
- ISH:
-
In situ hybridization
- DEGs:
-
Differentially expressed genes
- CEA:
-
Carcinoembryonic antigen
- CA19-9:
-
Carbohydrate antigen 19 − 9
- FJX1:
-
Four-jointed box protein 1
- FC:
-
Fold change
- GO:
-
Gene ontology
- KEGG:
-
Kyoto encyclopedia of genes and genomes
- OS:
-
Overall survival
- TMAs:
-
Tissue microarrays
- FFPE:
-
Formalin-fixed, paraffin-embedded
- CRC:
-
Colorectal cancer
- FIT:
-
Fecal immunochemical test
- GSEA:
-
Gene set enrichment analysis
- ECM:
-
Extracellular matrix
- CC:
-
Cellular component
- BP:
-
Biological process
- MF:
-
Molecular function
- TF:
-
Transcription factor
- GDC:
-
Genomic data commons
Acknowledgements
We thank the patients who participated in this study and the staff at the Department of Pathology, First Affiliated Hospital of Nanchang University, for technical assistance. Furthermore, we acknowledge the anonymous reviewers for their supportive and constructive contributions.
Funding
The funding bodies did not engage in the study’s design, data management, or manuscript preparation. This research was supported by grants from the Science and Technology Program of the Administration of Traditional Chinese Medicine of Jiangxi Province (Grant Nos. 2023B1190 and 2024B0385) and the Science and Technology Program of the Health Commission of Jiangxi Province (Grant No. 202410118).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
This study was approved by the Ethics Committee of Jiangxi Provincial People’s Hospital, with the ethical approval number JXPPH-202310172. All procedures were conducted in strict accordance with the principles set forth in the Declaration of Helsinki.
Consent to participate
Informed consent was obtained from all individual participants involved in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Liu, H., Wan, L. & Fang, Q. A bioinformatics and experimental approach identifies glycoprotein-based diagnostic and prognostic biomarkers for colon adenocarcinoma. Sci Rep (2026). https://doi.org/10.1038/s41598-026-52427-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-52427-5
